INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 16, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,264 | $30.63 | 503,264 |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,264 | -- | -- |
| Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,720 | $314.31 | 505,720 |
| Aug 27, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,720 | -- | -- |
| Feb 11, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 189,463 | $9.49 | 1,257,806 |
| Feb 11, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 189,463 | -- | -- |
| Dec 19, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,705 | $21.25 | 1,068,343 |
| Dec 19, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,705 | -- | -- |
| Dec 12, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,599 | $260.44 | 1,115,994 |
| Dec 12, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,599 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.